Open Access
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Andrew Kei-Yan Ng, Pauline Yeung Ng, April Ip, Kui Kai Lau, Chung-Wah Siu
DOI: 10.1136/svn-2021-001294 Published 2 September 2022
Andrew Kei-Yan Ng
1
Cardiac Medical Unit, Grantham Hospital, Hong Kong, Hong Kong
Pauline Yeung Ng
2
Department of Adult Intensive Care, Queen Mary Hospital, Hong Kong, Hong Kong
3
Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
April Ip
3
Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
Kui Kai Lau
3
Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
4
The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, Hong Kong
Chung-Wah Siu
3
Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong

Submit a Response to This Article
No eLetters have been published for this article.
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Andrew Kei-Yan Ng, Pauline Yeung Ng, April Ip, Kui Kai Lau, Chung-Wah Siu
Stroke and Vascular Neurology Aug 2022, 7 (4) 310-318; DOI: 10.1136/svn-2021-001294

Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Andrew Kei-Yan Ng, Pauline Yeung Ng, April Ip, Kui Kai Lau, Chung-Wah Siu
Stroke and Vascular Neurology Aug 2022, 7 (4) 310-318; DOI: 10.1136/svn-2021-001294
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Andrew Kei-Yan Ng, Pauline Yeung Ng, April Ip, Kui Kai Lau, Chung-Wah Siu
Stroke and Vascular Neurology Aug 2022, 7 (4) 310-318; DOI: 10.1136/svn-2021-001294